Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy.

Abstract:

:Terfenadine is a selective histamine H1-receptor antagonist which, in pharmacodynamic studies, is devoid of central nervous system depressant activity. In clinical studies terfenadine is well tolerated and at a dose of 60mg administered twice daily the drug provides effective relief of symptoms in patients with allergic rhinitis (seasonal and perennial), allergic dermatological conditions (particularly chronic urticaria), and other histamine-mediated disorders. Terfenadine is superior to placebo, has a more rapid onset of action than astemizole and is as effective as most other histamine H1-receptor antagonists, in relieving rhinitis symptoms. In allergic rhinitis, terfenadine relieves ocular symptoms to a greater extent (but nasal symptoms to a lesser extent) than inhaled corticosteroids. Administration of oral terfenadine with inhaled sodium cromoglycate (cromolyn sodium) or an inhaled corticosteroid appears more effective than terfenadine alone. Despite the absence of CNS depressant activity in pharmacodynamic studies, sedation is the adverse effect most frequently associated with terfenadine treatment. However, it is important to realise that the incidence of this adverse effect is similar in terfenadine and placebo recipients, and is less frequent than with traditional histamine H1-receptor antagonists. In conclusion, terfenadine is a clinically effective antihistamine which has an improved adverse effect profile compared with classic histamine H1-receptor antagonists. Like other nonsedating antihistamines, it can be considered as a first-line agent in the treatment of allergic rhinitis and chronic urticaria. With additional clinical experience, the drug could find a similar role in other disorders in which a histamine H1-receptor antagonist is indicated.

journal_name

Drugs

journal_title

Drugs

authors

McTavish D,Goa KL,Ferrill M

doi

10.2165/00003495-199039040-00006

subject

Has Abstract

pub_date

1990-04-01 00:00:00

pages

552-74

issue

4

eissn

0012-6667

issn

1179-1950

journal_volume

39

pub_type

临床试验,杂志文章,评审

相关文献

DRUGS文献大全
  • Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0666-0

    authors: Garnock-Jones KP

    更新日期:2017-01-01 00:00:00

  • Uraemic pruritus: clinical characteristics, pathophysiology and treatment.

    abstract::Pruritus is a common complication of end-stage renal disease (ESRD), affecting about one-third of dialysis patients. It is a chronic, unpleasant symptom with a strong negative impact on patients' quality of life, often inducing sleeplessness and mood disorders. Recent data show that it is also associated with increase...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969030-00002

    authors: Manenti L,Tansinda P,Vaglio A

    更新日期:2009-01-01 00:00:00

  • Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

    abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199200441-00002

    authors: Fuenmayor NT,Faggin BM,Cubeddu LX

    更新日期:1992-01-01 00:00:00

  • Cidofovir.

    abstract::Cidofovir is a nucleotide analogue which inhibits viral DNA polymerase and is effective against human cytomegalovirus (CMV) infection. It is phosphorylated to its active form by cellular enzymes. With the long intracellular half-life of its metabolites, cidofovir can be administered weekly during induction and every o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652020-00006

    authors: Lea AP,Bryson HM

    更新日期:1996-08-01 00:00:00

  • Levetiracetam: a review of its use in epilepsy.

    abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204490-000000000-00000

    authors: Lyseng-Williamson KA

    更新日期:2011-03-05 00:00:00

  • Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::The original article can be found online. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01407-8

    authors: Scott LJ

    更新日期:2020-09-01 00:00:00

  • Sacituzumab Govitecan: First Approval.

    abstract::Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01337-5

    authors: Syed YY

    更新日期:2020-07-01 00:00:00

  • Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

    abstract::Alectinib (Alecensa(®)) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0329-y

    authors: McKeage K

    更新日期:2015-01-01 00:00:00

  • Antiepileptic drug development in children: considerations for a revisited strategy.

    abstract::The European Commission and the European Parliament have acknowledged the specific need for a proper evaluation of new drugs in children. The evaluation of the antiepileptic drugs (AEDs) available on the market illustrates the deficit in therapeutic trials for childhood epilepsy syndromes. Currently, the development o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868010-00002

    authors: Chiron C,Dulac O,Pons G

    更新日期:2008-01-01 00:00:00

  • Interaction of lipoproteins with the artery wall.

    abstract::Atherosclerosis can be defined in terms of the processes involved rather than in morphological terms, and there is evidence for possible roles of the macrophage in atherogenesis. The relevance of hyperlipidaemia to the morphogenesis of the atherosclerotic plaque is important, and this has been described in animal mode...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800363-00012

    authors: Woolf N

    更新日期:1988-01-01 00:00:00

  • Gram-positive cocci infections in intensive care: guide to antibacterial selection.

    abstract::The incidence of multiresistance in Gram-positive cocci causing infections in critically ill patients admitted to the intensive care unit (ICU) has increased notably in recent years. Thus, therapeutic proposals have been modified according to the emergence of multiresistant cocci and adapted to epidemiological markers...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200666060-00003

    authors: Alvarez-Lerma F,Grau S,Gracia-Arnillas MP

    更新日期:2006-01-01 00:00:00

  • Pharmacological interventions for the induction of ovulation.

    abstract::Ovulation induction is the most common medical intervention for the treatment of infertility. Clomifene is generally the first treatment choice for patients with amenorrhoea, unless there is profound hypothalamic deficiency. When clomifene fails to induce ovulation, menotropins (human menopausal gonadotrophin) or gona...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550030-00006

    authors: Collins JA,Hughes EG

    更新日期:1995-09-01 00:00:00

  • Correction to: Pexidartinib: First Approval.

    abstract::The original article has been corrected. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01280-5

    authors: Lamb YN

    更新日期:2020-03-01 00:00:00

  • Prehospital administration of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

    abstract::25 patients have been included in a randomised trial aimed to compare prehospital and hospital administration of anisoylated plasminogen streptokinase activator complex (AP-SAC). Patients were first seen, at home, by a noncardiologist doctor working in a mobile-care unit and were then evaluated for entry into the stud...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00042

    authors: Castaigne AD,Duval AM,Dubois-Rande JL,Herve C,Jan F,Louvard Y

    更新日期:1987-01-01 00:00:00

  • Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

    abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363200-00008

    authors: Keating G,Figgitt D

    更新日期:2003-01-01 00:00:00

  • An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.

    abstract::This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0377-y

    authors: Elshoff JP,Cawello W,Andreas JO,Mathy FX,Braun M

    更新日期:2015-04-01 00:00:00

  • The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0565-4

    authors: Seiler T,Hutter G,Dreyling M

    更新日期:2016-04-01 00:00:00

  • Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

    abstract::Cefdinir (Omnicef) is an oral third-generation cephalosporin with good in vitro activity against many pathogens commonly causative in community-acquired infections. The drug provides good coverage against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae, the most common...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464130-00004

    authors: Perry CM,Scott LJ

    更新日期:2004-01-01 00:00:00

  • Somatropin (Zorbtive): in short bowel syndrome.

    abstract::A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464120-00008

    authors: Keating GM,Wellington K

    更新日期:2004-01-01 00:00:00

  • Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.

    abstract:BACKGROUND:The combination of an inhaled corticosteroid (ICS) and a long-acting bronchodilator is recommended in the treatment of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patie...

    journal_title:Drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00003495-200868140-00004

    authors: Tashkin DP,Rennard SI,Martin P,Ramachandran S,Martin UJ,Silkoff PE,Goldman M

    更新日期:2008-01-01 00:00:00

  • Management of gastroenteritis in early childhood.

    abstract::The most important aspect of modern management of acute diarrhoeal illness in children is that of oral rehydration therapy, and drug therapy is very rarely indicated. Despite the dramatic decline in mortality and morbidity in recent years, there is still the need for continuing education in the appropriate use of oral...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199244010-00005

    authors: Davies A,Jenkins HR

    更新日期:1992-07-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0960-0

    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • Guillain-Barré syndrome: epidemiology, pathophysiology and management.

    abstract::Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently af...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464060-00003

    authors: Kuwabara S

    更新日期:2004-01-01 00:00:00

  • Use of oral rehydration therapy in acute watery diarrhoea. A practical guide.

    abstract::Various foods and fluids have been used in traditional treatments for diarrhoeal illnesses in infants and children for centuries. During the last 2 decades, however, with the advent of an improved scientific understanding of oral rehydration, effective treatment of dehydrating diarrhoea has been improved, expanded and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141040-00005

    authors: Sack DA

    更新日期:1991-04-01 00:00:00

  • Drug treatment of scleroderma.

    abstract::Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud's phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice. Raynaud's phenomen...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161030-00008

    authors: Leighton C

    更新日期:2001-01-01 00:00:00

  • [Review of current pharmacologic treatment of pain].

    abstract::Pain is the main reason prompting patients to consult their physicians. In acute conditions, pain has a very particular significance as a warning sign, enabling the physician to attempt a diagnosis. Nevertheless, its detrimental effect upon the individual (even in the case of acute pain) and its cost to society are no...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700532-00005

    authors: Brasseur L

    更新日期:1997-01-01 00:00:00

  • Guide to the use of proton pump inhibitors in adult patients.

    abstract::Proton Pump Inhibitors (PPIs) are widely used in the treatment of acid-peptic diseases. Their mechanism of action involves inhibition of the H-K-adenosine triphosphatase enzyme present in the parietal cells of the gastric mucosa. Because PPIs are the most potent inhibitors of gastric acid secretion available, they eff...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868070-00004

    authors: Boparai V,Rajagopalan J,Triadafilopoulos G

    更新日期:2008-01-01 00:00:00

  • Myocardial infarction. Secondary prevention with nifedipine.

    abstract::The rationale for the use of nifedipine in patients with acute myocardial infarction (MI) is based on the various cardiovascular actions of the compound: reduction of myocardial oxygen consumption by attenuation of cardiac and vascular smooth muscle tension; augmentation of oxygen and substrate supply after increased ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.2165/00003495-199100422-00007

    authors: Rafflenbeul W,Ebner F

    更新日期:1991-01-01 00:00:00

  • Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

    abstract::Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli-derived L-asparaginase (hereafter referred as E. coliL-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to E....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01120-1

    authors: Heo YA,Syed YY,Keam SJ

    更新日期:2019-05-01 00:00:00

  • Tipranavir: a review of its use in the management of HIV infection.

    abstract::Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durab...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868100-00006

    authors: Orman JS,Perry CM

    更新日期:2008-01-01 00:00:00